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The role of sentinel node biopsy
in breast cancer management:
an overview
completed, including removal of the thoracic wall muscles. The
need to remove the axillary nodes at the same time was suggest-
ed by clinical and pathological considerations. Radical mastecto-
my, applied in the last years of the nineteenth century by Halsted
(1), achieved two goals: it reduced the number of local recurrenc-
es and improved patients chances of survival. As most of the
patients treated at that time had advanced cancer, the removal of
metastatic axillary nodes was of the utmost importance.
Moreover, it soon become evident that axillary dissection was
useful in forecasting disease prognosis and in achieving local
control of the axilla.
Then there were some attempts to improve the results by wid-
ening the surgical boundaries to include supraclavicular and in-
ternal mammary nodes en bloc with part of the thoracic wall (2, 3).
Nevertheless, these superradical procedures were not able to
achieve any therapeutic improvement compared to Halsteds clas-
sic mastectomy (4). On the contrary, it was weighed up if or how
much it was possible to reduce surgical resection without wors-
ening long term results of therapy. Surgeons started to perform a
modified radical mastectomy that allowed the preservation of the
pectoralis major, sacrificing just the pectoralis minor to make eas-
ier lymphoadenectomy, which had much better cosmetic and func-
tional results than radical mastectomy (5). Then Auchincloss 
after proving that a two level axillary lymph node resection was as
effective as a three level one  suggested a radical mastectomy
with preservation of both pectoralis major and minor and resec-
tion of just the first two lymph nodal levels in the axilla (6).
By the Seventies modified mastectomies had nearly replaced
radical mastectomy according to Halsted.
In the following decade all studies were aiming towards dis-
covering if a surgical treatment that allowed the patient with a small
carcinoma to preserve her breast could be able to control the
disease as well as  if not better than  a wider resection. This
smaller resection (just the quadrant that contains the cancer with
first and second level axillary lymph nodes) should be followed by
radiotherapy on the remaining breast tissue (7, 8).
In the last few years the greater awareness of people, a better
diffusion of screening programmes and the improvement of diag-
nostic procedures have led to a progressive and rapid reduction of
breast cancer mean size at the diagnosis. In the period 198995
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Abstracts
Regional lymph nodes surgical management is an integral part
of breast cancer therapy. One of the most important therapeu-
tic problems is the risk of surgical treatment which is too wide
or inadequate due to the lack of correct presurgical information
on the conditions of regional lymph nodes. For melanoma the
problem was solved combining surgical accuracy with the slight-
est surgical resection, using sentinel node biopsy.
In breast cancer the removal of axillary nodes proved to be un-
necessary in more than 50% of cases. The first international
studies on the use of sentinel node biopsy in breast carcinoma
for the identification of patients who do not need axillary clear-
ance suggest the high accuracy of the technique. Some practi-
cal problems still exist, however, and the optimisation of the
method is not yet complete.
The use of sentinel node biopsy in breast cancer treatment might
be able to provide distinctive clinical information, which can
improve our knowledge about the diseases biological behav-
iour and about its treatment.
Key words: breast, axillary nodes, sentinel node, dye,
lymphoscintigraphy, g-probe
The first surgical attempts to achieve control over breast cancer
were just a tumour resection: it was soon obvious that this treat-
ment was not sufficient. To avoid local recurrences with their se-
vere relative complications total mastectomy also needed to be
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this value reached about 1.5 cm: by extrapolation, we can foresee
that within ten years the mean size of diagnosed breast cancer
will be about 1 cm (9). Therefore in most cases the so-called
QUART  which is performed by removing the lesion with a 2 to 3
cm margin of healthy tissue with the respective skin, the underly-
ing muscles fascia and axillary lymph nodes of all levels and com-
pleted with radiotherapy of residual breast tissue  is an adequate
therapy and is used, with minimal variations, all over the world. The
current trend is to get a further reduction of the breast tissue that
has to be resected to reach a simple lumpectomy, completing the
procedure with further chemo- or radio therapy. The results for this
kind of procedure are conflicting and depend on the number of
data to be considered: the most important of these factors seems
to be the presence of cancer cells in the resection margins. This
occurrence, however, seems to affect just local recurrence rate, not
survival or distant metastasis (10, 11, 12, 13, 14).
Anyhow, this search for procedures is oriented to improve the
quality of patient life by taking into consideration the cost-effec-
tiveness of these techniques, steering clinical choices to a better
use of disposable resources while maintaining the same thera-
peutic effectiveness, and is supported by clinical observation that
often the nodes resected with primary tumour are healthy.
But, even in the early Seventies, it was doubtful if axillary lymph
nodes resection was so effective for survival. A study of the
National Surgical Adjuvant Breast Project published in 1985 (15)
compared ten years survival of randomised groups of breast can-
cer patients with clinically negative axillary nodes treated respec-
tively with: radical mastectomy, total mastectomy with axillary dis-
section just at lymph nodes metastasis appearance and total mas-
tectomy with regional nodes irradiation. Significant statistical dif-
ferences were not found in any group survival in spite of the fact
that about 40% of patients who underwent lymphoadenectomy
had axillary metastasis and, presumably, in patients of both the
other groups the rate of lymph nodes metastasis was the same.
So for the first time Halsteds principle of surgical radicality, which
had influenced breast cancer treatment for almost a century, was
placed in doubt.
These new changes in breast cancer treatment were important
because they demonstrated it was not necessary to use maiming
operations, with dramatic effects on both patient body and mind.
They showed breast cancer as systemic and not an organ disease
from the beginning, with axillary metastasis in the role of the first
sign of a special biological behaviour of that certain tumour.
We are arriving now at modern surgical oncology, which does
not regard widening the extent of surgical resection as the main
way to achieve a better prognosis, but recognises as its main aim
the maintenance of the highest quality of life jointly with the great-
est therapeutic efficacy by means of a rational modulation of the
operation.
There exists a well known linear relationship between primary
tumour size and axillary nodes metastasis rates. This rises from a
0% rate for Tis tumours, to a 3% rate in T1a, to 7% in T1b, to 32%
in T1c, and as high as 44% and 60% for T2 and T3 (16). Altogeth-
er, for tumours smaller than 2 cm, axillary metastasis rate is about
28% with a trend, over time, to diminish in accordance with medi-
an size reduction of diagnosed cancers (17).
At present, when performing an axillary lymph nodes resec-
tion on two or three levels, in two thirds of cases the surgeon
removes healthy nodes doing an unnecessary operation and ex-
posing the patient to risk of secondary complications. These com-
plications are often mild and temporary but sometimes go on for
a long time and worsen patient quality of life even though they do
not put their survival at risk. Among these complications the most
frequent and persistent is lymphedema, which shows severely in
28% of patients who underwent level III axillary clearance (18), in
a soft but perceptible way in 1520% of patients who underwent
level II axillary dissection and just as a different arm size in 40% of
cases (18, 20, 21).
Some other complications which can follow axillary lymph
nodes dissection are: seroma formation in post-operatory course,
restriction of shoulder movements, numbness and pain that ap-
pear respectively in 9% and 78% of cases. Altogether in 15% of
patients symptoms attributable to axillary surgery are severe
enough to interfere with their daily lives (21).
Considering all these data, it could seem correct to perform full
axillary lymph node clearance just in case of axillary metastasis.
Local axillary recurrence, if not treated, leads to unfavourable prog-
nosis, is often difficult to treat surgically and has disappointing de-
velopments (22). In all other patients it was stated that axillary clear-
ance of healthy nodes does not improve long term survival.
Nevertheless axillary nodal status is one of the most impor-
tant prognostic factors, together with primary tumour size, and
cannot be substituted by other factors even if considered all to-
gether. Unfortunately, the only clinical examination has false neg-
ative results in about 35% of cases (23) and more complex instru-
mental examinations are also not able to determine undoubtedly
that a certain node, especially if very small, is the site of metasta-
sis. The only technique able to identify lymph nodes metastasis at
present is Positron Emission Tomography (PET), with a sensitivity
that ranges from 90 to 100%, but just for lymph nodes 2 cm or
more in size (24).
Axillary clearance remains currently the most accurate predic-
tor of overall axillary node status and was recommended by the
Consensus Conference of the National Institute of Health at
Bethesda in 1992 to stage the disease and control regional diffu-
sion of cancer.
Nevertheless, the attempts to find a less aggressive alterna-
tive to full axillary clearance are progressing. From Veronesi et al.,
it results that cancer cells follow a well known way in the progres-
sion through the nodes and they seldom deflect from their route,
going on tidily from I° to III° level. The so-called skip metastases
occur in less than 2% of cases (17). So, if it was possible to know
beforehand that there were no nodal metastases at level I°, it might
be reasonably safe to avoid II° and III° level removal. On the other
hand, when level I° has metastases, the other levels are involved
in 41% of cases. Moreover, about 10% of patients with one I° level
involved node and about … of patients with two I° level nodes in-
volved have metastases in other levels. Altogether, about 16% of
breast cancer patients have metastases in all three axillary levels,
whereas II° and III° level metastases are present in about 40% of
patients with one axillary involvement and in 28% of patients with
breast cancer 2 cm or smaller in size.
From these data it is clear that resection of just I° level nodes
could be inadequate in a great number of patients with I° level
involvement and that, in the same patients, it could shorten the
disease-free interval and overall survival too because it was dem-
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onstrated that survival is directly related to the number of removed
axillary nodes.
Since nodal metastases are rare in cancers smaller than 2 cm
(1013%), it was proposed that in these cases the resection could
be limited just to level I° nodes (23). This way of acting is in conflict
with Mustafa et al. (25) whose data showed  in a large series 
the reduced prognostic value of tumour size. The paper demon-
strated an increase in importance of other two factors: patient age
and histological grading of cancer. Among young women, nodal
metastases occurrence can be greater than expected in very small
cancers and lead to underestimating the extent of disease.
Partial or sampling lymphoadenectomy has a high likelihood of
false negative results that reach even 40%; facing this fact the smaller
incidence of surgical complications loses any importance (26).
Although total axillary clearance with a complete histological
examination is the golden standard to which all other procedures
are compared, an alternative to take into consideration is sentinel
node biopsy, first applied by Morton in melanoma.
Sentinel node is the first node where lymphatic flow coming from
the neoplastic region arrives. It is identified trough intradermic ad-
ministration of vital dye: this rapidly enters the lymphatics and leads
to a blue-staining of the nearest node that is assumed to be most
likely to harbour metastases, because it is the node which first drains
the region in which the tumour exists. Using this technique, Morton
et al. (26) were able to identify in melanoma a sentinel node in 80% of
cases. Later this rate grew to 85% by some other AA (27).
Of course, the procedures major issue was if sentinel node
was able to predict lymph node status of all the draining region. In
Mortons original series, histological examination, performed on
surgical resected nodes, demonstrated a direct relation between
sentinel node and whole regional lymphatic basin status in 98%
of cases. The false negative rate was reduced to only 1%.
With such encouraging results, all efforts were made to im-
prove the technique using Tc-labelled sulphur colloid injected in
the region which contains the tumour and a g-camera (lymphos-
cintigraphy) or a manual probe used during surgical operation to
map regional lymph nodes. Using both blue dye and lymphoscin-
tigraphic methods, sentinel node identification was possible in
97% of cases (28).
Scintigraphic method is simpler than the blue dye one because
this could be difficult to follow, especially when lymphatic drainage
is deep and to apply it correctly the physician has to be very familiar
with it. At present, sentinel node scintigraphic identification is com-
monly employed in melanoma with practically no errors (30, 31).
In breast cancer too both sentinel node detection techniques
are employed. An intra or subdermal injection of blue dye is per-
formed in the tumour or tumour surrounding area. The dye rapidly
enters the lymphatics and 510 min later some blue stained lym-
phatic vessels that lead to a node coloured in blue  sentinel
node  can be visible. This technique is not entirely simple be-
cause of the propensity of the dye to pass through lymphatic ves-
sels walls and spread all over, making it hard for the surgeon sen-
tinel node identification (26, 29). Nevertheless, identification rates
improve rapidly after a short period of operators experience: fa-
miliarity with this technique raises identification rates from 65% to
94% for an experienced surgeon (32).
The second technique employs Tc-labelled colloids whose par-
ticles are small enough to rapidly enter lymphatic vessels and large
enough to be phagocytosed in the first node entered. From exper-
imental studies, the best size for the particles seems to be about 80
nm. (33). Thus the particles are not able to enter the bloodstream
and assure a high node-to-background uptake ratio. As the senti-
nel node is identified, with images acquired firstly at 10 min and
later every 15 min until visualisation, the overlying skin is marked.
During the surgical operation, performed some hours later,
the radiotracer still in the node is revealed by a hand held detector
(g-probe) that guides the surgeon onto the sentinel node and con-
firms the uptake.
In a recent trial by Veronesi et al. this technique allowed for the
correct diagnosis of axillary lymph nodes status in 97.5% of pa-
tients while an American multicentric trial performed in more than
400 patients refers a 97% diagnostic accuracy (34).
If we compare both methods, it appears evident that the lym-
phoscintigraphic technique gives higher sensitivity and more di-
agnostic accuracy than the blue dye one in melanoma (35) and in
breast cancer (36).
Using sentinel node technique in breast cancer allows the sur-
geon to apply less invasive surgical management with a better cost-
benefit ratio both for the patient and for the community. The pathol-
ogist too can get a more accurate study on the resected node. It
would be impracticable to subject all nodes from a total axillary clear-
ance (certainly more than 10, if the clearance is accurate) to serial
sections (3 to 5 each node), immunohistochemical examinations and
molecular analysis, but the same techniques can be easily applied
on just one node. Some recent papers highlight the value of evalua-
tions performed employing monoclonal antibodies against epithe-
lial antigens on serial node sections as well as standard hematoxy-
lin-eosin staining: with these more sensitive analyses the rate of
diagnosed node metastasis rises from 8 to 41% (38, 39).
These micrometastases, diagnosed with more refined tech-
niques, seem to have some clinical implications: retrospective
studies show that those patients who have axillary micrometastas-
es will have a worse prognosis than those who have no axillary
metastases at all (37, 38).
On the basis of these considerations, we can easily under-
stand that sentinel node immunohistochemical analysis could not
be carried out on frozen sections during surgery but must be per-
formed after definitive surgery, putting off full axillary clearance if
sentinel node biopsy is positive. Immediate examination by fro-
zen section, actually, has a sensitivity of 8085% even though with
a specificity of 100%. The absence of false-positive cases allows
the surgeon to perform an immediate complete axillary clearance
in those patients whose nodes are positive at a first standard ex-
amination on frozen sections and to put off till a second operation
those patients whose nodes will result positive just at a post-oper-
ative examination ( about 10% ). Recently, Veronesi et. al. described
a quick immunohistochemical method performed on frozen sec-
tions able to be employed for intraoperatory diagnosis on sentinel
node biopsy (40). This technique  still to be evaluated  seems
to require just one hour but it is complex, it needs 2 or 3 patholo-
gists at work at the same time and it makes the operation longer
(41). Apposition methods with cytological studies are simple and
quick but have a low sensitivity (6065% ) and do not add any-
thing to the accuracy of frozen sections (42).
In conclusion, early experiences on sentinel node technique
use in breast cancer therapy seem promising: the first data col-
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lected confirm that it can be employed in early breast cancer to
identify those patients who, free of axillary nodes metastases, could
get from axillary clearance just complications and discomfort with-
out any therapeutic advantage.
At the same time sentinel node biopsy seems to be able to
properly predict axillary node status and can provide the same prog-
nostic and therapeutic indications as the total axillary clearance.
Surprisingly this method, which consists in resecting just one node,
seems to be able, because this only node is accurately examined,
to diagnose otherwise occult micrometastases. The prognostic and
therapeutic value to be attributed to these data is still to be as-
sessed but there is no doubt that somehow they will lead to a deep-
er knowledge of the biological behaviour of this cancer.
The problem remains still unresolved of patients (luckily rare)
whose lymphatic vessels drain into the internal mammary chain or
into supraclavicular nodes: in this case axillary clearance would be
useless and should be replaced by different surgical procedures.
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